HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Middleton, P. G. Articles by Williams, B. Search for Related Content PubMed PubMed Citation Articles by Middleton, P. G. Articles by Williams, B.

Combination aerosol therapy to treat Burkholderia cepacia complex

¹ Ludwig Engel Centre for Respiratory Research, Dept of Respiratory Medicine, and ³ Dept of Pharmacy, Westmead Hospital, Westmead, NSW, ² Dept of Microbiology, Queensland Health Pathology Service, The Prince Charles Hospital, Chermside, Qld, Australia.

CORRESPONDENCE: P. G. Middleton, University of Sydney, CF Unit, Ludwig Engel Centre for Respiratory Research, Dept of Respiratory Medicine, Westmead Hospital, Westmead, 2145, NSW, Australia. Fax: 61 2 9845 7286. E-mail: peterm@westgate.wh.usyd.edu.au

Keywords: Aerosol, amiloride, Burkholderia cepacia complex, cystic fibrosis, tobramycin

Received: October 30, 2004
Accepted May 3, 2005

Burkholderia cepacia infection in cystic fibrosis (CF) patients is associated with significant morbidity and mortality, yet no definitive treatment is currently available. This report describes a new approach to treat B. cepacia infection in CF patients, using a combination of amiloride and tobramycin aerosols.

Four adults with the typical clinical syndrome of CF were recruited after repeated positive sputum cultures for B. cepacia. Aerosols of amiloride and tobramycin were given three times daily for 1–6 months, and repeated sputum cultures were collected to assess efficacy.

Three of the four patients treated with the combined therapy eradicated B. cepacia from their sputum cultures for at least 2 yrs, and there were no adverse events.

This novel combination may provide a new therapeutic option for Burkholderia cepacia infections. Furthermore, the strategy of combining antibiotics with ion transport agents may have ramifications for the treatment of other multi-resistant organisms.

This article has been cited by other articles:

				I Eser, T Altan, J E Stahl, M D Aydin, N Inan, Z Kapran, and O F Yilmaz Two cases of Burkholderia cepacia endophthalmitis. Br. J. Ophthalmol., September 1, 2006; 90(9): 1211 - 1211. [Full Text] [PDF]